scholarly journals Use of Combination Therapy in Malaria Treatment and Prevention in Indonesia

2021 ◽  
Vol 4 (1) ◽  
pp. 29-33
Author(s):  
Reqgi First Trasia

Malaria is still a health problem in Indonesia. Treatment of malaria often encounters obstacles. Resistance to various malaria drugs in some areas causes an increase in morbidity and mortality due to malaria. Rational use of malaria drugs that are still effective and available is important. Therefore, this article will review the use of combination therapy in the treatment of malaria in Indonesia. The purpose of using combination therapy is to increase the efficacy of treatment and slow down the occurrence of resistance to each component in the drug. From this article, it can be concluded that artemisinin-based combinations using artemisinin derivatives are still effective for use as combination therapy against malaria. This combination can be a fixed combination or co-administered. The drugs that can be combined are 4-aminoquinoline, antifolate, 4-quinoline-methanol, artemisinin and its derivatives, antibiotics, and atovaquone-proguanil. It is hoped that the combination of these drugs can still be used for a long period of time, remain safe, effective and affordable by the community.

Author(s):  
OJS Admin

Malnutrition remains the most serious health problem and the single leading contributor of child morbidity and mortality among children under 5 years of age.Worldwide, malnutrition causes almost one-third of the children's deaths each year which is approximately 2.6 million even before they turn five.


2007 ◽  
Vol 17 (5_suppl) ◽  
pp. 28-30 ◽  
Author(s):  
C. Migdal

Several fixed combination products are now available in glaucoma management. Considerations when selecting combination therapy include safety, finding the best combination of mechanisms of action. Combigan® is one such product that has been shown to be more effective than either of its constituent agents, brimonidine or timolol, used alone. It has at least a similar intraocular pressure (IOP)-lowering effect as the concomitant use of its two constituents, and it produces a significant additional lowering of IOP in patients who switch from other therapies, including Cosopt®. Combigan has high patient satisfaction ratings.


2017 ◽  
Vol 10 (1) ◽  
Author(s):  
Manolis K. Chatzis ◽  
Dimitris Psemmas ◽  
Elias Papadopoulos ◽  
Christelle Navarro ◽  
Manolis N. Saridomichelakis

Author(s):  
Kimberly Livingstone ◽  
Daniel B. Herman ◽  
Naomi Adler ◽  
Ezra S. Susser

Homelessness is associated with both poorer health and higher risk of morbidity and mortality. Recent research suggests that with growing availability of antiretroviral therapy and the expansion of housing alternatives for chronically homeless persons, HIV is no longer a leading cause of death among the homeless. Nonetheless, HIV prevalence is significantly higher among homeless persons than among their housed counterparts. This chapter examines the association between HIV/AIDS and homelessness in the United States. After providing a brief overview of homelessness and the characteristics of specific homeless subpopulations, we discuss HIV prevalence, transmission, treatment and prevention among people who are homeless in the United States.


Sign in / Sign up

Export Citation Format

Share Document